LifeVantage (NASDAQ:LFVN) Releases FY 2024 Earnings Guidance

LifeVantage (NASDAQ:LFVN) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.570-0.670 for the period, compared to the consensus earnings per share estimate of 0.600. The company issued revenue guidance of $202.0 million-$205.0 million, compared to the consensus revenue estimate of $209.3 million.

LifeVantage Trading Up 7.5 %

Shares of NASDAQ:LFVN opened at $6.57 on Monday. LifeVantage has a 12-month low of $3.04 and a 12-month high of $8.69. The business’s fifty day simple moving average is $6.51 and its 200-day simple moving average is $6.37. The company has a market capitalization of $83.44 million, a PE ratio of 23.46 and a beta of 0.80.

LifeVantage Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 31st will be given a $0.04 dividend. This is a boost from LifeVantage’s previous quarterly dividend of $0.04. The ex-dividend date is Friday, May 31st. This represents a $0.16 dividend on an annualized basis and a dividend yield of 2.44%. LifeVantage’s dividend payout ratio (DPR) is presently 50.00%.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.